Project Grant W81XWH2210972

The Defense Health Agency awarded a $468,672 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Georgia College & State University. The grant, titled "The Inclusive Cancer Care Research Equity (ICCARE) for Black Men Consortium," will fund research focused on examining health-seeking behaviors, decision-making, psychosocial effects, and coping mechanisms among Black men with prostate cancer. The project will also test the efficacy of...

Federal Cooperative Agreement Summary The University of Miami received a $4.67 million Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Centers Support Grants program (CFDA 93.397), awarded on September 5, 2025, with a completion date of August 31, 2030. The award funds the PROMISE (Personalized Outreach and Multifaceted Interventions for Screening Enhancement) initiative, which addresses disparities in anal cancer and cervical cancer prevention, screening, and...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...

The U.S. Department of the Army Medical Command awarded a $4,623,272 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Mayo Clinic Jacksonville (A Nonprofit Corporation), doing business as Scott Lynch MD. The grant, titled "The Inclusive Cancer Care Research Equity (ICCARE) for Black Men Consortium," will support advanced biomedical research focused on transforming healthcare for military service members and the broader public. The four-year...

This federal Project Grant award, totaling $477,869.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant aims to develop tailored, multilevel cervical cancer interventions for ethnically diverse Black women, including African American women and Black African immigrant women. The key objectives are to: 1) identify multilevel determinants of routine cervical cancer screening and follow-up adherence among these populations,...

Federal Cooperative Agreement Summary Award Details: The National Cancer Institute awarded a five-year Cooperative Agreement valued at $5,041,790 to The Regents of the University of California, San Francisco under the Cancer Centers Support Grants program (CFDA 93.397), effective August 1, 2025 through July 31, 2030. This U54 Specialized Programs of Research Excellence (SPORE) award supports the UCSF Cancer Health Disparities SPORE, which investigates the interplay of tumor genomic and immune...

Federal Cooperative Agreement Summary The University of North Carolina at Chapel Hill received a $2.255 million Cooperative Agreement from the National Cancer Institute under the Cancer Centers Support Grants program (CFDA 93.397), awarded September 4, 2025, with completion targeted for July 31, 2030. This award establishes a Cancer Health Disparities Specialized Program of Research Excellence (SPORE) in endometrial cancer, addressing one of the largest health disparities in U.S. cancers. The...

Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a $2.56 million Cooperative Agreement to The University of Texas MD Anderson Cancer Center under the Cancer Centers Support Grants program (CFDA 93.397) on August 22, 2025, with a completion date of July 31, 2030. This award funds a Lymphoma Outcomes Specialized Program of Research Excellence (SPORE) focused on addressing health disparities in lymphoma outcomes among African American and Hispanic patients. The...

This $509,510 Project Grant was awarded by the National Cancer Institute (NCI), through the Cancer Cause and Prevention Research (CFDA 93.393) program, to the University of Alabama at Birmingham (UAB) on April 1, 2025. The grant will fund a 5-year investigation to characterize the influence of structural racism on associations between mutational signatures, T cell immunity, and the excess risk of monoclonal gammopathy of undetermined significance (MGUS) observed in African American...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...